Company intelligence / Profile preview
ParcelBio
San Francisco, California, United Statesparcelbio.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
ParcelBio is developing a proprietary platform for the programmable delivery of mRNA medicines, aiming to overcome key challenges in targeted RNA therapeutic delivery. The company’s technology, STAmP, seeks to enable safe and specific targeting of mRNA without nanoparticles. No clinical results have been published yet; the company appears preclinical with a focus on platform development.
- Therapeutic areas
- Other
- Modalities
- mRNA therapeutics (Ribonucleic acid medicines)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Y Combinator (accelerator/funding partner)
Beyond the preview
Go deeper on ParcelBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ParcelBio.